logo-loader

IPO Roundup: Chinese real estate management company Fangdd, two US biopharmas to go public this week

Oyster Point Pharma and CNS Pharmaceuticals also expect to make their public debuts

Golden bull emerging from the word 'IPO'
Fangdd claims to be the largest real estate marketplace in China, featuring 911,000 of the country’s roughly 2 million agents on its platform

Three companies are slated to open trading this week.

Pricing Tuesday

Fangdd Network Group (NASDAQ:DUO), an online real estate marketplace based in Shenzhen China, plans to offer 7 million shares at a price between $13 and $16 per share in order to raise $98 million. 

The company claims to be the largest real estate marketplace in China, featuring 911,000 of the country’s roughly 2 million agents on its platform as of December 31.

In June, the company had 131 million properties in its database, one of the largest such databases in China according to Frost & Sullivan.

Pricing Wednesday

Oyster Point Pharma Inc (NASDAQ:OYST), a Princeton, New Jersey-based biopharmaceutical company developing therapies to treat ocular surface diseases, hopes to raise $85 million by offering 5 million shares at a price between $16 and $18 per share.

Its lead candidate, varenicline, is a nasal spray designed to treat the signs and symptoms of dry eye disease. In a Phase 2 trial of 182 patients, varenicline demonstrated statistically significant improvements over a placebo.

The company began a Phase 3 trial in July and expects topline results in mid-2020 with a potential New Drug Application to follow.

Pricing Thursday

CNS Pharmaceuticals Inc (NASDAQ:CNSP), a Houston biotechnology company focused on brain cancer therapies, is looking to raise $10 million by offering 2.1 million shares at a price between $4 and $6 per share. 

The company is developing drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its lead drug candidate, Berubicin, is designed to treat glioblastoma, a type of brain cancer currently considered to be incurable, the company said.

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tonix Pharmaceuticals CEO talks through recent pre-clinical and clinical...

Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) CEO Seth Lederman sat down with Proactive at the BIO CEO & investor Conference in New York. Lederman says the biopharma company had recently unveiled the pre-clinical results of TNX-801, its live virus horsepox vaccine that prevents...

4 hours, 14 minutes ago

2 min read